Latest news with #Genome
Yahoo
3 days ago
- Business
- Yahoo
ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement
Proxy Sets Company on a Path to Attract the Optimal Crypto Treasury Strategy Increase in Authorized Shares to 1 Billion Would Position the Company to Attract Industry-Leading Market Participants and High-Value Crypto Treasury Transactions UNIONDALE, NY, July 29, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the 'Company' or 'ProPhase') a next generation biotech, genomics and consumer products company, will hold a Special Meeting of Shareholders on August 29, 2025, at 4:00 p.m. Eastern Time at 273 Merrick Road, Lynbrook, NY 11563. The Board of Directors has unanimously recommended shareholders vote 'FOR' all proposals at the upcoming Special Meeting. The Company is seeking to increase the authorized shares to 1 billion to strategically position the Company to attract high-value structured transactions and industry-leading participants - including market makers, asset managers, and innovators in the crypto treasury space - enabling the Company to pursue and optimize a forward-looking digital asset treasury strategy. The Company filed a Preliminary Proxy Statement filed with the U.S. Securities and Exchange Commission on July 28, 2025. For additional information regarding the proposals to be acted upon at the upcoming Special Meeting of Stockholders, please refer to the Company's Preliminary Proxy Statement. A copy of the Preliminary Proxy Statement is available free of charge through the SEC's website at Shareholders are encouraged to review the definitive proxy statement when it becomes available, as it will contain important information regarding these proposals. 'Our Board remains focused on strengthening ProPhase Labs' ability to innovate, reward talent, and create value for our shareholders,' said Ted Karkus, Chairman and Chief Executive Officer of ProPhase Labs. 'The proposals we are presenting at the Special Meeting are key steps that will equip us with the flexibility and resources needed to pursue exciting growth opportunities and respond to a rapidly changing industry landscape.' Mr. Karkus continued, 'In parallel, the company remains focused on its goal of collecting approximately $50 million from our Covid accounts receivables, which would dovetail perfectly with our potential crypto treasury strategy, as well as to continue to develop our BE-Smart™ esophageal cancer test that has enormous potential and to pursue strategic alternatives for Nebula Genomics, including a potential sale.' About ProPhase Labs Inc. ProPhase Labs Inc. (Nasdaq: PRPH) ('ProPhase') is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We're revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs' valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. Forward-Looking Statements Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our expectations regarding the future revenue growth potential of each of our subsidiaries, our expected timeline for commercializing our BE-Smart Esophageal Cancer Test, our expectations regarding future liquidity events, the success of our efforts to collect accounts receivables and anticipated timeline for any payments relating thereto, and our ability to successfully transition into a consumer products company. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. These forward-looking statements are subject to risks and uncertainties and actual results may differ materially. Details about these risks and uncertainties can be found in our filings with the SEC. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements. Important Additional Information and Where to Find It In connection with the proposed actions described herein, ProPhase Labs, Inc. will file a preliminary proxy statement and other materials with the U.S. Securities and Exchange Commission (the "SEC"). BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF PROPHASE LABS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER RELEVANT DOCUMENTS IN THEIR ENTIRETY, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE MATTERS TO BE CONSIDERED AT THE SPECIAL MEETING. Stockholders will be able to obtain, free of charge, copies of the proxy statement (when available), any amendments or supplements to it, and other documents filed by ProPhase Labs with the SEC at the SEC's website at Copies will also be available on the Company's website This press release does not constitute a solicitation of any vote or approval. No proxy card, voting instruction form, or other means of voting will be accepted by ProPhase Labs or any of its representatives at this time. This press release is not an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. All information in this press release is current as of the date indicated. ProPhase Labs undertakes no duty to update any such information, except as required by law. If you have questions concerning the proposals or how to participate in the Special Meeting, please contact the Company at investorrelations@ Media Relations and Institutional Investor Contact:ProPhase Labs, Retail Investor Relations Contact:Renmark Financial CommunicationsJohn Boidman: jboidman@ (416) 644-2020 or (212) in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hindu
23-07-2025
- Health
- The Hindu
Genetic screening emerging as key to better IVF success rates, say Kolkata experts
As World IVF Day (July 25) approaches, fertility experts in Kolkata say there is an urgent need to integrate genetic screening into mainstream fertility care to improve chances of healthy babies and avoid failed pregnancies. Emili Banerjee, Genetic Counsellor at Genome – The Fertility Centre in Kolkata said that the procedure of Preimplantation Genetic Testing (PGT) to select embryos without abnormalities for implantation can have better assurance of a successful pregnancy and has better chances of a healthy baby. She emphasied on how genetic testing can be beneficial 'not only for those who are seeking IVF due to infertility, but also patients who have had recurrent pregnancy failures.' Genome held a session on on July 23, on how to 'Decode Infertility with Genetics' where doctors and clinicians spoke at length about how advanced genetic screening is transforming the success rates of IVF and identifying the underlying causes of unexplained infertility. There was an emphasis on how genetic screening has been of exceptional service to patients who had no hope of bearing a healthy child due to being carriers of serious inherited conditions. Some of them have genetic issues in their extended families which lead to failed pregnancies, but couples remain unaware of it for years. 'It is not obligatory for couples with genetic problems to seek sperm or egg donation, to opt for adoption or to refrain from marriage or childbearing entirely,' Genome Director of Clinical Service, Dr. Sanjay Das Gupta said, 'PGT helps to determine if the baby would be born with inherited disorders such as Thalassemia or Spinal Muscular Atrophy (SMA) before the pregnancy even occurs.' As a medical expert in the field of IVF, Dr Das Gupta suggested that when a couple is not able to conceive through natural conjugal relationship, but both the partners are healthy and have no apparent issues with their reproductive systems, there can be underlying genetic issues that can lead to unsuccessful pregnancies. That is why in such cases, genetic screening can help bring about positive change. An integrated, team-based strategy can optimize the outcomes of assisted reproductive technology and guide patients to make informed reproductive decisions. The session conveyed how genetic screening is not rare or optional but rather a keystone in modern fertility care.
Time of India
16-07-2025
- Health
- Time of India
Gujarat to launch tribal genome mapping project across 17 districts
Ahmedabad: In a first-of-its-kind initiative, Gujarat will begin a large-scale genome mapping project focusing exclusively on its tribal communities. Teams of scientists will travel to towns and villages in 17 districts with significant tribal populations to collect 4,158 biological samples, including blood, leading to the creation of about 2,000 whole genome sequences (WGS) representing over 20 tribal communities. Officials said that while Gujarat samples were earlier part of the national-level Genome India Project, this is the first dedicated effort to build a reference genome database solely for the tribal population of one state. The project, hailed as a major step in integrating science with tradition, was discussed during a session on 'Creation of Reference Genome Database for Tribal Population in Gujarat' held on Wednesday. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad Kuber Dindor, minister of tribal development, and Kunwarji Halpati, minister of state (Tribal Development), chaired the session, which was attended by scientists from the Gujarat Biotechnology Research Centre (GBRC), officials from the department of science and technology, and tribal development experts. "This is the first such initiative in the country, focusing exclusively on tribal groups," said an official. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo The genome data will provide valuable micro-level insights into the genetic health and diversity of Gujarat's tribal population, which constitutes nearly 15% of the state's total population. Communities involved in the study include Bamcha, Garasia Bhil, Dholi Bhil, Chaudhari, Dhanka, Tadvi, Valvi, Dubla, Gamit, Gond, Kathodi, Kukna, Kunbi, Nayaka, Pardhi, Patelia, Rathwa, Warli, Kotwalia, and others. The Sidi community, known for its African ancestry, from Amreli, Bhavnagar, Jamnagar, Junagadh, Rajkot, and Surendranagar will also be part of the initiative. As part of the study design, each tribe will include at least one genetic trio—samples collected from both parents and a child—to trace inherited genetic traits. The survey will involve only healthy individuals aged 18 and above, with no visible blood disorders. Officials also emphasized a target of 50% women representation in the sampling. Local administrative bodies will assist in information dissemination and obtaining informed consent. Dindor described the project as a bridge between science and tradition, adding that it will play a crucial role in addressing the health and welfare needs of tribal populations through personalized and community-level genetic insights. Pointers: Understanding Tribal Genetics - The project will provide a comprehensive repository of genetic markers that will help experts assess the probability of specific diseases or health conditions - National surveys have indicated a relatively higher prevalence of anaemia and malnutrition among the tribal population, along with a relatively higher infant mortality rate - Apart from health, the markers will help create a distinct profile of communities, ranging from genetic attributes to their interaction with larger population markers
Finextra
15-07-2025
- Business
- Finextra
Genome and Huch partner for SEPA payments alerts
Lithuania-based electronic money institution Genome has partnered with HUCH to enable instant detection of incoming SEPA payments. 1 This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author. Payment delays cost businesses revenue, and the speed of payments can never be underestimated, especially in a highly competitive business environment. Genome's partnership with HUCH drives payment innovation forward, offering a game-changing solution for fast-moving companies that eliminates the risk of payment delays. Businesses that utilize the services offered by Genome with HUCH can now confirm incoming clients' transfers immediately. All thanks to the integration of an innovative API and webhooks, which enable instant notifications about client-to-business payments. Genome's instant notification feature was created based on the team's firsthand experiences working with iGaming companies. Real-time payment detection is critical for licensed betting and gambling platforms, where every second counts. This technical innovation enables businesses using the Genome-HUCH integrated solution to receive notifications about deposits as soon as the funds reach their Genome account. In the case of SEPA Instant, this can happen within seconds. It means companies can react to such C2B transactions instantly and streamline account top-ups without worrying about missing a payment. Real-time payment notifications are valuable across a wide range of industries where speed and responsiveness are critical. E-commerce platforms can instantly confirm payments and proceed directly to order processing, thereby improving delivery times and customer satisfaction. Digital service providers, especially those offering subscription-based access, can activate services immediately upon receipt of payments, with no delays and no manual checks. In fast-paced digital environments, the ability to react instantly to client actions, such as purchases, renewals, or deposits, is a key driver of both customer experience and operational efficiency. Industries such as fintech, online marketplaces, and iGaming platforms also benefit from seamless, real-time transaction flows that help ensure uninterrupted user experiences and smooth operations. "Fast-moving businesses like fintech apps, online marketplaces, and digital platforms rely on real-time responsiveness. Our instant payment alerts are designed to automate key processes, eliminate delays, and enhance cash flow visibility. We believe more businesses will adopt such solutions to stay competitive in a landscape where seamless financial experiences are no longer a luxury but an expectation," explained Genome's CEO, Daumantas Barauskas. "The impact of instant payment alerts on businesses is immediate. Businesses are now able to confirm incoming payments instantly, adjust operations in real-time, and offer a smoother customer experience. It's a clear example of how tech partnerships can directly improve performance and decision-making for modern businesses," noted HUCH's CEO, Quentin Madelaine. ________________________________________
Hindustan Times
07-07-2025
- Health
- Hindustan Times
Covid cases decline in Pune after brief rise in May
After a slight surge in Covid-19 cases in May, Pune city reported a decline in numbers in the month of June, Pune Municipal Corporation (PMC) officials said. However, the situation improved in June, with the number of cases decreasing to 68, they said. (FILE) According to PMC officials, in May, the city reported 93 Covid cases, a significant increase after months of very low activity. However, the situation improved in June, with the number of cases decreasing to 68, they said. Furthermore, from January to April this year, Pune had reported just one COVID-19 case, indicating almost no presence of virus circulation in the city during that period. The rise in May was not serious and was handled well due to ongoing health surveillance and prompt response measures, said the civic health officials. 'The increase in May was minor, and there is no reason for concern at this time. Many cases tested positive in private city hospitals were incorrectly reported to be from the PMC limits. We are continuing our surveillance to ensure early detection and control,' said Dr Vaishali Jadhav, assistant health officer, PMC. PMC authorities have urged citizens to stay alert, maintain hygiene, and consult doctors if they experience symptoms. People should avoid panic and instead focus on being cautious, especially people in high-risk categories. Besides, vaccination, timely testing, and responsible behaviour are still important in keeping COVID-19 under control, they said. As per the statement issued by the Public Health Department, on Sunday Maharashtra reported 8 fresh COVID-19 cases. Of which, 2 are from PMC, 5 are from Mumbai and 1 from Kolhapur. Since January 2025, as many as 2577 covid cases and 41 deaths amongst the infected have been reported. Also, the state has a recovery rate of 95.92%. Besides, since January, as many as 2569 covid cases and 41 deaths amongst the infected have been reported. Furthermore, currently, there are 64 active Covid cases in the state. Since January, Mumbai has reported 1012 covid cases, of which the highest 551 cases were reported in June alone, said Dr Sandeep Sangale, joint director of Health Services. Dr Sangale said the number of cases have declined in the state. 'The team is conducting regular surveillance of influenza-like illness (ILI) and severe acute respiratory syndrome (SARI) patients. Around 5% of ILI patients and all SARI patients are tested for COVID-19. Besides, samples of all positive patients are sent for Whole Genome Sequencing.'
